Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Asasantin ER Experimental Formulations
NCT02273544Phase 1Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2002
- Primary completion
- Oct 2002
01
Overview
Phase 1, randomised, open-label trial of dipyridamole + aspirin in stroke and Transient Ischemic Attack (TIA) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Urinary excretion of dipyridamole at day 3. Started Sep 2002; status: terminated.
02
Drugs
dipyridamole + aspirin
03
Conditions
strokeTransient Ischemic Attack (TIA)
Beyond the preview
Go deeper on NCT02273544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02273544.